Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729
4.12.2024 13:00:00 EET | Business Wire | Press release
We are excited to share our latest development status.
We are pleased to announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase II/III clinical trial of DFP-17729 in combination with TS-1 versus TS-1 alone in patients with pancreatic cancer after third-line treatment was approved.
In a Phase I/II study of DFP-17729 in combination with TS-1 in patients with end-stage pancreatic cancer, no significant difference was observed against the control treatment (TS-1 or gemcitabine), but stratified analysis showed that when patients in the third-line or later treatment were treated for more than 6 weeks, DFP-17729 in combination with TS-1 showed a predominant median overall survival (mOS) prolongation (9.0 months vs. 6.1 months) and a significant correlation was also observed between urinary alkalinization and mOS in pancreatic cancer patients treated with DFP-17729, as key proof of concept. We had presented these results at the ESMO Gastrointestinal Cancers Congress 2024 and the 55 Annual Meeting of the Japan Pancreas Society, where much attention was paid to the presentation.
DFP-17729 is a novel approach to neutralize the acidic cancer microenvironment, and several patents on related inventions have been granted in major countries around the world, and its potential of efficacy has been published in peer-reviewed journals.
We will first identify DFP-17729 as a treatment for refractory pancreatic cancer, for which effective treatment is not yet available, and then seek to expand the indication to other types of cancer through partnership with major global pharmaceutical companies.
Please take notice of our own innovative approach for miserable cancer patients and contact us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204497142/en/
Contacts
Inquires
Yasundo Yamasaki, Ph.D.
Director, Business Development
Delta-Fly Pharma Inc.
Head office: Tokushima 771-0117, Japan
Phone: +81-3-6231-1278
E-mail: yyamasaki1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/en/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.delta-flyp
harma.co.jp%2Fen%2F&esheet=54161588&newsitemid=20241204497142&lan=en-US&anchor=h
ttps%3A%2F%2Fwww.delta-flypharma.co.jp%2Fen%2F&index=1&md5=adcd527d539f6849e5052
6d1e02039b2
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logistics Reply Introduces the LEA AI Agent Authority Model - Bringing Governed Agentic AI Into Warehouse Execution With LEA Dynamic Intelligence5.10.2026 11:00:00 EEST | Press release
Logistics Reply, the Reply group company specializing in innovative solutions for supply chain execution and warehouse management, today unveiled the LEA AI Agent Authority Model, a new practical framework delivered alongside LEA Reply Dynamic Intelligence, enabling organizations to deploy AI agents with the right authority for each task—not maximum autonomy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005360127/en/ Logistics Reply introduces the LEA AI Agent Authority Model, a new practical framework delivered alongside LEA Reply Dynamic Intelligence, enabling organizations to deploy AI agents with the right authority for each task—not maximum autonomy. As AI moves from assistance into live warehouse execution, organizations need a governed way to decide how much authority agents should have in each operational context. Without clear criteria, adoption can stall or place additional risk on operational teams. The aim i
Technology Innovation Institute Completes Asteroid-Landing Probe for Landmark Emirates Mission to the Asteroid Belt5.10.2026 10:42:00 EEST | Press release
The Technology Innovation Institute (TII) has revealed the UAE-built probe it has developed for the Emirates Mission to the Asteroid Belt (EMA). The probe will soon travel to Colorado, USA, for final integration with the MBR Explorer spacecraft ahead of its planned 2028 launch. In a historic first, TII’s probe will image two planets and seven asteroids — flying past six asteroids in the main belt before culminating in a rendezvous with and landing on the seventh, 269 Justitia. If successful, the landing will make Justitia only the seventh asteroid in history to be reached on the surface by the probe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006586478/en/ H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council (ATRC), and H.E. Belhoul Al Falasi, Chairman of the UAE Space Agency, sign a model of the UAE-built probe developed by the Technology Innovation Institute (TII) for the Emirates Mis
JEOL: Sales launch of HAXIS: The New Low-angle Ion Milling Scanning Electron Microscope5.10.2026 10:30:00 EEST | Press release
JEOL Ltd. (President & CEO Izumi Oi) announces the development of its new low‑angle ion‑milling scanning electron microscope, HAXIS, and will commence sales on October 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928207899/en/ HAXIS Low-angle Ion Milling Scanning Electron Microscope HAXIS Low-angle Ion Milling Scanning Electron Microscope Background of development As advanced semiconductor device structures continue to shrink and grow more complex, it has become difficult to contact and measure microscale circuits using nano-manipulators. In addition, contact caused by probing may affect the analysis target, necessitating new failure analysis methods. JEOL has conducted long-term research on the passive voltage contrast (PVC) detection technology and established a method for stable, highly reproducible PVC observation technology through the advancement of detectors and sample preparation techniques. HAXIS is JE
Slate Asset Management and OneIM Agree to Acquire Portfolio of Grocery-Anchored Essential Real Estate in the Greater Oslo Region Valued at Approximately €250 Million5.10.2026 09:30:00 EEST | Press release
Slate Asset Management ("Slate"), a global investor and manager focused on essential real estate and infrastructure assets, and One Investment Management (“OneIM”), a global alternative investment manager, today announced they have agreed to acquire a portfolio of eight grocery-anchored retail parks in Norway from Tellus Eiendom AS. The portfolio is located in the Greater Oslo region and is anchored by Norway's leading grocery operators and discount retailers. “We are pleased to be expanding our European Essential real estate platform with this significant acquisition,” said Brady Welch, Co-Founding Partner of Slate Asset Management. “These eight retail parks sit in dominant locations along major transport corridors around Oslo. The portfolio is anchored by Norway's strongest grocery operators and benefits from CPI-linked lease structures, designed to provide durable, inflation-protected cash flows. We look forward to applying our active management to unlock the portfolio’s full potent
Bial Showcases Parkinson’s Research at MDS 20265.10.2026 09:00:00 EEST | Press release
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, is presenting 16 scientific posters at the International Congress of Parkinson’s Disease and Movement Disorders (MDS 2026), taking place in Seoul, Korea, from 4 to 8 October. Reflecting Bial’s commitment to listening to and learning directly from people living with Parkinson’s, two presentations cover research initiatives focused on understanding their experiences, perspectives, and priorities. The first is the Patient Endpoint Preference Project (PEPP), an ongoing multinational observational study that seeks to identify and prioritise the symptoms and outcomes that matter most to people living with Parkinson’s. The second is the TRACK-PD study, which provides insights into treatment routines and adherence behaviours, contributing to a better understanding of the challenges experienced in real-world settings. These findings may support the integration of the perspectives of people living wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom